18F-Labelled exendin to image GLP-1 receptor-expressing tissues: From niche to blockbuster?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 3, 2012, Pages 461-462

  Boerman, Otto C ^a   Gotthardt, Martin ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EXTENDIN 4 F 18; EXTENDIN 4 IN 111; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; EXENDIN 4; FLUORINE; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; VENOM;

BENIGN TUMOR; BRAIN; BREAST; CELL TRANSPLANTATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULINOMA; INTESTINE; KIDNEY; LUNG; NONHUMAN; NOTE; PANCREAS; PANCREAS ISLET BETA CELL; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; CHEMISTRY; FEMALE; METABOLISM; METHODOLOGY; SCINTISCANNING;

ANIMALS; FEMALE; FLUORINE RADIOISOTOPES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULINOMA; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; VENOMS;

EID: 84859640488     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-2020-9     Document Type: Note

References (13)

1. Andralojc K, Brom M, Claessens-Joosten L, Bos D, Oyen W, Boerman O, Gotthardt M. Longitudinal imaging of transplanted islets in a rat model with SPECT. Eur J Nucl Med Mol Imaging 2011;38 Suppl 2:S144.
2. Brom M, Oyen WJ, Joosten L, Gotthardt M, Boerman OC. 68Galabelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging 2010;37:1345-55.
3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-10. (Pubitemid 36042113)
4. Gotthardt M, Fischer M, Naeher I, Holz JB, Jungclas H, Fritsch HW, Béhé M, Göke B, Joseph K, Behr TM. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging 2002;29:597-606. (Pubitemid 34439319)
5. Kiesewetter DO, Gao H, Ma Y, Niu G, Quan Q, Guo N, Chen X. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. Eur J Nucl Med Mol Imaging 2012. doi:10.1007/s00259-011-1980-0.
6. Löhr M, Klöppel G. Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin-dependent) diabetes mellitus and microangiopathy. Diabetologia 1987;30:757-62. (Pubitemid 17163000)
7. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007;48:736-43. (Pubitemid 47604973)
8. Pauly RP, Demuth HU, Rosche F, Schmidt J, White HA, Lynn F, McIntosh CH, Pederson RA. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor IIethiazolidide. Metabolism 1999;48:385-9. (Pubitemid 29116004)
9. Pattou F, Kerr-Conte J, Wild D. GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. N Engl J Med 2010;363:1289-90.
10. Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC. Insulin secretion in type 1 diabetes. Diabetes 2004;53:426-33. (Pubitemid 38174559)
11. Wicki A, Wild D, Storch D, Seemayer C, Gotthardt M, Behe M, Kneifel S, Mihatsch MJ, Reubi JC, Mäcke HR, Christofori G. [Lys40(Ahx-DTPA-111In)NH2]- Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptortargeted therapy for insulinoma. Clin Cancer Res 2007;13:3696-705. (Pubitemid 46955134)
12. Wild D, Mäcke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med 2008;359:766-8.
13. Wild D,Wicki A, Mansi R, Béhé M, Keil B, Bernhardt P, Christofori G, Ell PJ, Mäcke HR. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med 2010;51:1059-67.